Home
HelpTest ID BMIPB Borrelia miyamotoi Detection, PCR, Blood
Ordering Guidance
This assay does not detect the Borrelia species that cause Lyme disease. If Lyme disease is suspected, order SLYME / Lyme Antibody Modified 2-Tier with Reflex, Serum.
Specimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: 1 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Useful For
Aiding in the diagnosis of Borrelia miyamotoi infection in conjunction with clinical findings
Preferred method for detection of B miyamotoi using blood specimens
Testing Algorithm
For more information see Acute Tick-Borne Disease Testing Algorithm.
Method Name
Real-Time Polymerase Chain Reaction (PCR)
Reporting Name
Borrelia miyamotoi Detection, PCR, BSpecimen Type
Whole Blood EDTASpecimen Minimum Volume
0.3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated | 7 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
Clinical Information
Borrelia miyamotoi is a spirochetal bacterium, closely related to the Borrelia species that causes tick-borne relapsing fever (TBRF), and it is more distantly related to the Borrelia species that cause Lyme disease. This organism causes a febrile illness like TBRF, with body and join pain, fatigue, and, rarely, rash. B miyamotoi has been detected in Ixodes scapularis and Ixodes pacificus ticks. These ticks are also the vectors for Lyme disease, anaplasmosis, and babesiosis.
The preferred method for detecting B miyamotoi is real-time polymerase chain reaction. Less sensitive and specific methods for detecting B miyamotoi and agents of TBRF include serologic testing and identification of spirochetes in peripheral blood films or spinal fluid preparations. This assay does not detect the Borrelia species that cause Lyme disease.
Reference Values
Negative
Reference values apply to all ages.
Interpretation
A positive result indicates the presence of Borrelia miyamotoi DNA and is consistent with active or recent infection. While positive results are highly specific indicators of disease, they should be correlated with symptoms and clinical findings of tick-borne relapsing fever.
Cautions
Inadequate specimen collection or improper storage may invalidate test results.
After adequate treatment, Borrelia miyamotoi DNA may remain detectable for an unknown period of time.
Clinical Reference
1. Gugliotta JL, Goethert HK, Berardi VP, Telford SR III: Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013 Jan 17;368(3):240-245
2. Fomenko NV, Borgoyakov VY, Panov VV: Genetic features of DNA of Borrelia miyamotoi transmitted by Ixodes persulcatus. Mol Genet Microbiol Virol 2011;26:60-65. doi: 10.3103/S0891416811020054
3. Platonov AE, Karan LS, Kolyasnikova NM, et al: Humans Infected with Relapsing Fever Spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011 Oct;17(10):1816-1823
Method Description
The assay is performed on the Roche LightCycler (LC) 480 instrument, following DNA extraction on the Roche MagNA Pure. The LC 480 instrument amplifies and monitors the development of target nucleic acid (amplicon) after each cycle of polymerase chain reaction (PCR).
The DNA target for this PCR assay is a gene encoding the glycerophosphodiester phosphodiesterase (glpQ) gene specific to Borrelia species in the relapsing fever group. This gene is not found in Borrelia species that cause Lyme disease.
The specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer, which utilizes 1 hybridization probe with a donor fluorophore, fluorescein, at the 3' end, and a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5' end. When the target amplicon is present, the LC-Red 640 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid is confirmed by performing a melting temperature analysis of the amplicon; the presence or absence of a melting peak in the appropriate temperature range is used to determine if a specimen is positive or negative.(Unpublished Mayo method)
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 4 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87478
NY State Approved
YesForms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.